Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2025-12-24 @ 4:40 PM
NCT ID:
NCT02913066
Brief Summary:
Will meet the inclusion criteria of patients with esophageal squamous cell carcinoma, divided into 2 groups randomly:
Experimental group: radiotherapy combined with S-1 chemotherapy.
Control group: radiotherapy combined with S-1 chemotherapy and cisplatin.
Detailed Description:
Will meet the inclusion criteria of patients with unresectable esophageal squamous cell carcinoma, divided into 2 groups randomly:
Experimental group: radiotherapy combined with S-1 chemotherapy;
control group: radiotherapy combined with S-1 chemotherapy for first to 14 days and 29 \~ 42 days, plus cisplatin first 1\~ 4 days and 29 \~ 33 days. Using IMRT radiotherapy.
Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, or S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
Primary Outcome Measure is complete remission rate.
Secondary Outcome Measures are overall survival (OS) and Progression-Free-Survival (PFS) and toxicity.
Study:
NCT02913066
Study Brief:
Protocol Section:
NCT02913066